Reproductive Solutions Appoints IVF/ART Specialists to New Advisory Board


Will help advance the use of the ProteX Semen Collection Container to improve sample quality

DALLAS, April 27, 2022 /PRNewswire/ — Reproductive Solutions (RSI), creator of the patented, FDA-listed ProteX™ semen collection container, today announced the formation of an advisory board to help the company advance its mission to improved results of fertility treatments. The ProteX solution is at the heart of this mission with multiple studies documenting its ability to improve sample quality for in vitro fertilization and other assisted reproductive technologies.

Unlike urine sample cups traditionally used for semen collection, the ProteX Container uniquely combines an insulated design with an interior funnel that directs semen to a small retention well. This design prevents large temperature fluctuations, minimizes surface area exposed to the environment, and preserves a high quality sample for up to 48 hours compared to the 45-60 minutes of standard 50-year-old collection methods. Longer sample viability not only increases motility, sperm count, and fertilization ability, but also enables home collection that relieves pressure on men and eases bottlenecks in clinic laboratories of fertility.

At the American Association of Bioanalysts conference next month, Dr. Samuel Prien of Reproductive Solutions will present the results of a clinical study authored by Drs. Eric Forman and Zev Williams from Colombia University Fertility of nearly 2,000 patients where ProteX was compared to the traditional method of semen collection. The results of this study and others continue to suggest that ProteX provides higher quality sperm for use in assisted reproductive procedures such as IUI, IVF and possibly even ICSI.

Members of the Reproductive Solutions Advisory Board will help raise industry awareness of these benefits by interacting directly with IVF/ART professionals at industry meetings, assisting in the development of educational and training materials, providing opportunities to observe the implementation of ProteX in their clinical practices and offering strategic suggestions. to advance the adoption of ProteX based on their in-depth knowledge of the IVF/ART space. They will also share their views on industry trends to help guide new product development. Members include:

  • Richard G. Rawlins, Professor Emeritus of Obstetrics and Gynecology and Anatomy and Cell Biology at Rush Medical College in Chicago and past president of the Chicago Association of Reproductive Endocrinologists. Dr. Rawlins has also been actively involved in the development of accreditation standards for IVF clinical laboratories through his work on the executive committee of the Society for Assisted Reproductive Technology (SART) and through the American Association of Bioanalysts (AAB).
  • Jürgen LiebermanDirector of the Laboratories of the Fertility Center of Illinois since 2004. Working in the field of IVF since 1995 and certified as a High Complexity Clinical Laboratory Director by the American Board of Bioanalysis, Dr. Lieberman is also the Scientific Co-Chair of the Council of Physician and Scientists, the largest network private in the country. of physicians and embryologist dedicated to the field of human reproduction, and co-author of Vitrification in assisted human reproduction.
  • Matthew ‘Tex’ VerMilyea, Vice President of Scientific Advancement for TexasOvation Fertility, where he serves as the scientific resource and operational advocate for the national network of Ovation IVF laboratories. Prior to joining Ovation Fertility seven years ago, Dr. VerMilyea served as Scientific Director of Texas Fertility Centers, Scientific Director at Fertility Associates of New Zealandand Director of the Assisted Reproductive Technologies and Andrology Laboratories at The University of Pennsylvania Fertility care.
  • Marc Brignola, Global Vice President of Sales at Biotech Inc. with over a decade of sales and marketing experience providing state-of-the-art IVF/ART equipment and devices to reproductive labs and clinics in fertility around the world. Brignola began his IVF/ART career in field sales, responsible for the Midwest region of United States. Over the past 13 years, he has developed deep relationships with key people around the world.

The four advisory board members also sit on the Scientific Advisory Board of Reproductive Solutions, which provides scientific and medical expertise to assist the company in its efforts to improve semen collection methodology as a means of improving outcomes for infertile couples. .

“Gen X and Millennial couples who are trying to start families at a later age are faced with the reality that sperm quality declines with age. Therefore, getting the best possible sample to understand first the health of your sperm and then for use in IVF or other ART treatments is increasingly essential in helping infertile couples conceive,” said Diana Peninger, President and CEO of Reproductive Solutions. “Our ProteX collection method is the first advancement in this area since the inception of IVF, and all of our board members are committed to helping us make it the semen collection technology of choice for clinics. fertility.”

About Reproduction Solutions

Reproductive Solutions (RSI) is a medical device company dedicated to helping couples achieve their dream of having a family. Its flagship product, the ProteX home semen collection container, was developed by reproductive health specialists from Texas University of Technology Health Sciences Center. For more information visit

SOURCE Reproductive Solutions Inc.


Comments are closed.